- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05714683
Regulatory Post Marketing Surveillance (rPMS) studie av Rybelsus (oral Semaglutid) for å evaluere sikkerhet og effektivitet hos pasienter med type 2 diabetes mellitus i rutinemessig klinisk praksis i Korea
En multisenter, prospektiv, åpen etikett, enarms, ikke-intervensjonell, Regulatory Post Marketing Surveillance (rPMS) studie av Rybelsus® (oral Semaglutid) for å evaluere sikkerhet og effektivitet hos pasienter med type 2 diabetes mellitus i rutinemessig klinisk praksis i Korea
The aim of this study is to assess the safety and effectiveness of Rybelsus initiated according to label in adults with Type 2 Diabetes Mellitus (T2DM) under routine clinical practice conditions. Participants will get Rybelsus as prescribed by study doctor. The study will last for about 26 weeks.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Novo Nordisk
- Telefonnummer: (+1) 866-867-7178
- E-post: clinicaltrials@novonordisk.com
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Adult participants with T2DM, who initiate treatment with Rybelsus under routine clinical practice in Korea.
Beskrivelse
Inclusion Criteria:
- The decision to initiate treatment with commercially available Rybelsus has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study
- The participant with T2DM is scheduled to start treatment with Rybelsus based on the clinical judgment of their treating physician as specified in the approved label in Korea
- Informed consent is obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study
- Male/female age greater than or equal to (>=) 19 years at the time of signing informed consent
Exclusion Criteria:
- Participants who are or have previously been on Rybelsus therapy
- Known or suspected hypersensitivity to Rybelsus, the active substance or any of the excipients
- Previous participation in this study. Participation is defined as having given informed consent in this study
- Female participant who is pregnant, breast-feeding or intends to become pregnant and is of child-bearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by Korea regulation or practice)
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Family or personal history of multiple Endocrine Neoplasia Type 2 (MEN 2) or Medullary Thyroid Carcinoma (MTC)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Participants with T2DM
All participants will be treated with Rybelsus for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by Ministry of Food and Drug Safety (MFDS). |
All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number (Incidence) of adverse events (AEs)
Tidsramme: From baseline (week 0) to 26 weeks
|
Measured as count of events. |
From baseline (week 0) to 26 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number (Incidence) of hypoglycaemia Level 3 or Level 2
Tidsramme: From baseline (week 0) to 26 weeks
|
Hypoglycaemia Level 3 or Level 2 according to American Diabetes Association (ADA) guideline 2020 refers to: 1) Level 2: Glucose less than (<) 54 milligrams per deciliter (mg/dL) (3.0 millimoles per liter [mmol/L]); 2) Level 3: A severe event characterized by altered mental and/or physical status requiring assistance for treatment of hypoglycaemia. Measured as count of events. |
From baseline (week 0) to 26 weeks
|
|
Change in glycated haemoglobin (HbA1c)
Tidsramme: From baseline (week 0) to 26 weeks
|
Measured in percentage (%). |
From baseline (week 0) to 26 weeks
|
|
Participants achieving HbA1c target <7.0%
Tidsramme: At 26 weeks
|
Measured as count of participants (Yes/No). |
At 26 weeks
|
|
Change in fasting blood glucose (FBG)/fasting plasma glucose (FPG)
Tidsramme: From baseline (week 0) to 26 weeks
|
Measured in mg/dL. |
From baseline (week 0) to 26 weeks
|
|
Change in post prandial blood glucose (PPBG)/post prandial plasma glucose (PPPG)
Tidsramme: From baseline (week 0) to 26 weeks
|
Measured in mg/dL. |
From baseline (week 0) to 26 weeks
|
|
Change in body weight
Tidsramme: From baseline (week 0) to 26 weeks
|
Measured in kilogram (kg). |
From baseline (week 0) to 26 weeks
|
|
Dose of Rybelsus
Tidsramme: At 26 weeks
|
Measured in milligrams per day (mg/day). |
At 26 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NN9924-4652
- U1111-1243-9500 (Annen identifikator: World Health Organization (WHO))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .